Luuk F.P. Giesen

Dr. Luuk F.P. Giesen

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2026 in Clinical Chemistry
Verified
Journal Article
Open access
LGLuuk F.P. Giesen
Luuk F.P. Giesen
JRJeroen A Roest
Jeroen A Roest
FKFrederique M A Koopman
Frederique M A Koopman
MDMartine M L Deckers
Martine M L Deckers
HCHelena Chon
Helena Chon
RJRobert de Jonge
Robert de Jonge
Background: Automated phlebotomy has the potential to improve patient outcomes and address phlebotomist workforce challenges. The Autonomous Blood Drawing Optimization and Performance Testing trial (ADOPT, ClinicalTrials.gov NCT05878483) assesses performance, safety, and patient experience of an autonomous robotic phlebotomy device (ARPD) that utilizes multimodal imaging. Methods: Patients were recruited from outpatient phlebotomy departments in the Netherlands. In cohort 1, analytical equivalence was assessed by comparing within-subject test results from ARPD-collected and manually collected samples using Passing–Bablok regression analysis. In cohort 2, the ARPD was assessed in routine use. The primary performance endpoint was first-stick success rate; the primary safety endpoint was the rate of adverse events. Exploratory endpoints assessed pain and patient preference. Results: One hundred fifty-three patients were enrolled in cohort 1. No statistically significant differences were observed in activated partial thromboplastin time, prothrombin time, lactate dehydrogenase, aspartate transaminase, or platelet count, indicating analytical equivalence. A total of 1633 patients were enrolled in cohort 2. The overall first-stick success rate, in patients where the ARPD could identify a suitable vein, was 94.5% (95% CI, 93.3–95.5) and remained high in patients with difficult venous access (92.7%), obesity (97.4%), and age ≥65 years (93.4%). Adverse events, all mild, occurred at a rate of 0.6%. Ninety percent of patients reported far less (19%), less (32%), or similar pain (39%) compared with manual phlebotomy. Eighty-two percent indicated they would strongly prefer (16%) or prefer (31%) use of the ARPD in the future or had no preference (35%). Conclusions: Automated phlebotomy using the ARPD shows a favorable performance and safety profile and may improve patient experience. ClinicalTrials.gov Registration Number: NCT05878483

17 November 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
JRJeroen Roest
Jeroen Roest
LGLuuk F.P. Giesen
Luuk F.P. Giesen
THThijs C. van Holten
Thijs C. van Holten
MDMartine Deckers
Martine Deckers
HCHelena Chon
Helena Chon
RJRobert de Jonge
Robert de Jonge
Background/Objectives: Automated phlebotomy may improve preanalytical quality and access to venous blood testing. Prior work evaluating the Aletta Autonomous Robotic Phlebotomy Device (ARPD) demonstrated analytical equivalence. This study expanded the initial analytical validation to additional blood collection tubes and analytes and also assessed real-world hemolysis rates. Methods: The study was conducted in three hospital outpatient phlebotomy departments, including a site with a high prevalence of (hemato-)oncology patients. The within-subject analytical validation study included Greiner VACUETTE (Cohort 1) and BD Vacutainer (Cohort 2) serum, lithium heparin, and EDTA tubes. Equivalence of potassium, lactate dehydrogenase, hemolysis index, and complete blood count (CBC) with differential between paired ARPD-collected and manually collected samples was assessed using Passing–Bablok regression. Real-world ARPD hemolysis (>0.5 g/L free hemoglobin) rates were determined in a separate cohort (Cohort 3) and compared with site-specific manual hemolysis rates. Results: In the analytical validation study, 119 patients were included in the analysis (Cohort 1, n = 52; Cohort 2, n = 67). All tests met the predefined acceptability criteria. The hemolysis index was statistically significantly lower in ARPD-collected lithium heparin samples in Cohort 1. In real-world use (1368 ARPD venipunctures), the ARPD hemolysis rate was 0.0% (95% CI: 0.0–0.3%), significantly lower than manual phlebotomy (1.6%, p = 0.025). Conclusions: The study demonstrated analytical equivalence in a clinically complex population and found reduced ARPD hemolysis rates. The results further substantiate that the ARPD could improve patient care by reducing preanalytical errors.